

# CITATION REPORT

List of articles citing

**MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.**

**DOI: 10.1038/s41467-022-29397-z**  
**Nature Communications, 2022, 13, 1797.**

**Source:** <https://exaly.com/paper-pdf/135048234/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
8	CD117, BAP1, MTAP, and TdT Is a Useful Immunohistochemical Panel to Distinguish Thymoma from Thymic Carcinoma.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
7	Integrative Analysis of the Genomic and Immune Microenvironment Characteristics Associated With Clear Cell Renal Cell Carcinoma Progression: Implications for Prognosis and Immunotherapy. <i>Frontiers in Immunology</i> , <b>2022</b> , 13,	8.4	1
6	Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies. <b>2022</b> , 15,		5
5	Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma. <b>2022</b> ,		0
4	Novel synthetic lethality drug target in urothelial bladder cancer based on MTAP genomic loss. <b>2022</b> ,		0
3	Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas.		0
2	scDR: Predicting Drug Response at Single-Cell Resolution. <b>2023</b> , 14, 268		0
1	Methylthioadenosine phosphorylase deficiency in tumors: A compelling therapeutic target. 11,		0